Celltrion, Inc. (068270.KS)
068270.KS Stock Price Chart
Explore Celltrion, Inc. interactive price chart. Choose custom timeframes to analyze 068270.KS price movements and trends.
068270.KS Company Profile
Discover essential business fundamentals and corporate details for Celltrion, Inc. (068270.KS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Jul 2005
Employees
2.39K
Website
https://www.celltrion.comCEO
Hyong-Gi Kim
Description
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
068270.KS Financial Timeline
Browse a chronological timeline of Celltrion, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is ₩1.12K, while revenue estimate is ₩1.11T.
Earnings released on 21 Jul 2025
EPS came in at ₩820.14 surpassing the estimated ₩817.71 by +0.30%, while revenue for the quarter reached ₩961.46B , missing expectations by -3.78%.
Earnings released on 7 May 2025
EPS came in at ₩460.99 falling short of the estimated ₩598.56 by -22.98%, while revenue for the quarter reached ₩841.91B , missing expectations by -7.24%.
Earnings released on 27 Feb 2025
EPS came in at ₩1.08K surpassing the estimated ₩982.48 by +9.73%, while revenue for the quarter reached ₩1.06T , beating expectations by +6.18%.
Dividend declared on 27 Dec 2024
A dividend of ₩714.29 per share was announced, adjusted to ₩678.57. The dividend was paid on 1 Apr 2025.
Stock split effective on 27 Dec 2024
Shares were split 21 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Nov 2024
EPS came in at ₩415.22 falling short of the estimated ₩862.88 by -51.88%, while revenue for the quarter reached ₩881.93B , missing expectations by -10.34%.
Earnings released on 7 Aug 2024
EPS came in at ₩377.00 surpassing the estimated ₩297.59 by +26.68%, while revenue for the quarter reached ₩874.74B , beating expectations by +3.44%.
Earnings released on 9 May 2024
EPS came in at ₩108.00 falling short of the estimated ₩593.73 by -81.81%, while revenue for the quarter reached ₩736.98B , beating expectations by +0.54%.
Earnings released on 29 Feb 2024
EPS came in at ₩7.40 falling short of the estimated ₩566.38 by -98.69%, while revenue for the quarter reached ₩382.60B , missing expectations by -25.70%.
Dividend declared on 27 Dec 2023
A dividend of ₩525.00 per share was announced, adjusted to ₩500.00. The dividend was paid on 23 Apr 2024.
Earnings released on 7 Nov 2023
EPS came in at ₩1.56K surpassing the estimated ₩1.17K by +33.82%, while revenue for the quarter reached ₩672.29B , beating expectations by +7.50%.
Earnings released on 14 Aug 2023
EPS came in at ₩1.03K falling short of the estimated ₩1.14K by -9.02%, while revenue for the quarter reached ₩523.98B , missing expectations by -13.33%.
Earnings released on 8 May 2023
EPS came in at ₩1.16K surpassing the estimated ₩1.04K by +11.11%, while revenue for the quarter reached ₩597.56B , beating expectations by +1.23%.
Earnings released on 3 Mar 2023
EPS came in at ₩503.00 falling short of the estimated ₩869.80 by -42.17%, while revenue for the quarter reached ₩510.64B , missing expectations by -14.79%.
Dividend declared on 28 Dec 2022
A dividend of ₩375.00 per share was announced, adjusted to ₩375.00. The dividend was paid on 24 Apr 2023.
Stock split effective on 28 Dec 2022
Shares were split 26 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2022
EPS came in at ₩1.16K surpassing the estimated ₩970.05 by +19.74%, while revenue for the quarter reached ₩645.64B , beating expectations by +13.75%.
Earnings released on 5 Aug 2022
EPS came in at ₩1.28K surpassing the estimated ₩919.57 by +38.65%, while revenue for the quarter reached ₩596.07B , beating expectations by +2.04%.
Earnings released on 16 May 2022
EPS came in at ₩820.19 falling short of the estimated ₩919.76 by -10.83%, while revenue for the quarter reached ₩550.60B , missing expectations by 0.00%.
Earnings released on 16 Feb 2022
EPS came in at ₩845.19 falling short of the estimated ₩879.71 by -3.92%, while revenue for the quarter reached ₩621.91B , beating expectations by +5.87%.
Dividend declared on 29 Dec 2021
A dividend of ₩750.00 per share was announced, adjusted to ₩686.81. The dividend was paid on 22 Apr 2022.
Stock split effective on 29 Dec 2021
Shares were split 51 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2021
EPS came in at ₩931.37 falling short of the estimated ₩1.29K by -27.73%, while revenue for the quarter reached ₩400.96B .
Earnings released on 13 Aug 2021
EPS came in at ₩862.37 falling short of the estimated ₩1.10K by -21.56%, while revenue for the quarter reached ₩431.77B .
Earnings released on 17 May 2021
EPS came in at ₩1.33K surpassing the estimated ₩998.62 by +33.10%, while revenue for the quarter reached ₩456.97B .
Earnings released on 22 Feb 2021
EPS came in at ₩740.36 falling short of the estimated ₩1.09K by -31.95%, while revenue for the quarter reached ₩498.70B .
Stock split effective on 29 Dec 2020
Shares were split 51 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2020
EPS came in at ₩1.22K surpassing the estimated ₩1.07K by +13.60%, while revenue for the quarter reached ₩548.77B .
068270.KS Stock Performance
Access detailed 068270.KS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.